Fengxia Liu

Fengxia Liu

Auto-generated profile, based on publicly available information

Fengxia Liu

Department of Allergy, Weifang People’s Hospital, Weifang, People’s Republic of China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in LWT
Verified
Journal Article
Open access
ZYZhixuan Yang
Zhixuan Yang
XDXinke Duan
Xinke Duan
JYJinyan Yang
Jinyan Yang
HWHongdi Wang
Hongdi Wang
FLFengxia Liu
Fengxia Liu
SPSiyi Pan
Siyi Pan

1 January 2021 in Bioengineered
Verified
Journal Article
Open access
XWXiaoxu Wang
Xiaoxu Wang
HCHui Chen
Hui Chen
JLJingjing Liu
Jingjing Liu
LGLinlin Gai
Linlin Gai
XYXinyi Yan
Xinyi Yan
FLFengxia Liu
Fengxia Liu
Asthma is a chronic inflammatory disease characterized by airway remodeling and bronchial hyperresponsiveness. A variety of effector cells and cytokines jointly stimulate the occurrence of inflammatory response in asthma. Although the pathogenesis of asthma is not entirely clear, the possible roles of non-coding RNAs (ncRNAs) have been recently demonstrated. NcRNAs are non-protein-coding RNA molecules, such as circular RNAs (circRNAs), long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), which are involved in the regulation of a variety of biological processes. Mounting studies have shown that ncRNAs play pivotal roles in the occurrence and progression of asthma via competing endogenous RNA (ceRNA) regulatory networks. However, the specific mechanism and clinical application of ncRNAs and ceRNA regulatory networks in asthma have not been fully elucidated, which are worthy of further investigation. This paper comprehensively summarized the current progress on the roles of miRNAs, lncRNAs, circRNAs, and ceRNA regulatory networks in asthma, which can provide a better understanding for the disease pathogenesis and is helpful for identifying novel biomarkers for asthma.

29 August 2022 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
XZXiyan Zhang
Xiyan Zhang
XZXude Zhang
Xude Zhang
SFShaojie Feng
Shaojie Feng
XWXijuan Wang
Xijuan Wang
BGBeibei Guo
Beibei Guo
FLFengxia Liu
Fengxia Liu
Background: Allergic asthma is the most common type of asthma and often occurs in early life with increasing comorbidities, including atopic dermatitis and allergic rhinitis. MicroRNAs (miRNAs) are involved in the pathogenesis of numerous immune and inflammatory disorders, particularly allergic inflammation. The specific miRNA profiles of children with allergic asthma have not been fully delineated and still require in-depth study. Objective: This study aimed to identify the expression profile of miRNAs and constructed a network of the interactions between differentially expressed miRNAs and target mRNAs to provide novel insights into understanding the pathogenesis of allergic asthma. Materials and Methods: In this study, we performed high-throughput sequencing of peripheral blood mononuclear cells (PBMCs) from children in the acute phase of asthma. Bioinformatics approaches, including miRanda, Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) databases, were employed to predict novel therapeutic and diagnostic targets for allergic asthma. Real-time quantitative PCR was conducted to detect the expression of aberrantly expressed miRNAs. Results: One hundred and sixty-one differentially expressed miRNAs were identified in children with allergic asthma, including 140 conserved miRNAs and 21 novel miRNAs. A total of 8929 targeted mRNAs (44,186 transcripts) associated with differentially expressed miRNAs were predicted and significantly enriched in the cGMP-PKG signalling pathway, cholinergic synapse, and salivary secretion. We also found that miRNA-370-3p targeted PKG and MLCP molecules in the cGMP-PKG signalling pathway and was involved in the pathogenesis of allergic asthma. Conclusion: We identified the miRNA profile of PBMCs in children with allergic asthma and also found that miRNA-370-3p targeted PKG and MLCP molecules in the cGMP-PKG signalling pathway, which provides a novel insight into understanding the pathogenesis of allergic asthma and investigating new targets for the treatment of allergic asthma in children.

1 January 2021 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
ZXZhang Xu-De
Zhang Xu-De
GBGuo Bei-Bei
Guo Bei-Bei
WXWang Xi-Juan
Wang Xi-Juan
LHLi Hai-Bo
Li Hai-Bo
ZLZhang Li-Li
Zhang Li-Li
LFLiu Feng-Xia
Liu Feng-Xia
Background. Immunoglobulin E (IgE) is the most important promoter of allergic inflammation. However, there are few systematic studies on IgE in age range, genders, disease spectrum, and time regularity. Aim. To screen the common allergens, allergen spectrum, and IgE difference between type 2 inflammatory allergic diseases and other allergic diseases in Weifang, China. Methods. A retrospective study was performed by estimating patients’ clinical data suffering from allergic diseases (urticaria, pollinosis, allergic rhinitis, atopic dermatitis, and bronchial asthma) between May 2019 and April 2020 using an allergen detection kit of Macro‐Union Pharmaceutical. Results. 732 of the 1367 patients showed different antigen positive, and the positive rate was 53.5%. The most common allergens were dust mites, mixed fungi, Artemisia pollen, cat/dog dander, and cockroaches. There were 27.0% (369/1367) of the patients with single positive allergen‐specific IgE (sIgE), 26.5% (363/1367) with multiple‐positive IgE. The total immunoglobulin E (tIgE) levels varied with gender, age, and type of disease. There was a difference in the distribution of allergens between children and adults. A positive correlation between the serum‐specific IgE and the corresponding local inhaled allergen density was observed. Conclusions. In this study, we found that type 2 inflammatory allergic diseases have higher serum IgE and a higher probability of inhaled sIgE positive. According to age, gender, and condition, serological IgE detection of allergens provides new insight into the early diagnosis and prevention of allergic diseases.

1 August 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
KHKang He
Kang He
JZJie Zang
Jie Zang
TRTingting Ren
Tingting Ren
SFShaojie Feng
Shaojie Feng
MLMohan Liu
Mohan Liu
FLFengxia Liu
Fengxia Liu
Atopic dermatitis (AD) is a chronic and inflammatory skin disease with intense itchiness that is highly prevalent worldwide.The pathogenesis of AD is complex and closely related to genetic factors, immunopathogenic factors, environmental factors, and skin infections. Mesenchymal stem cells (MSCs) are non-hematopoietic progenitor cells derived from the mesenchymal stroma. They have anti-inflammatory, anti-apoptotic, and regenerative properties. Numerous studies demonstrate that MSCs can play a therapeutic role in AD by regulating various immune cells, maintaining immune homeostasis, and promoting the repair of damaged tissues. The key mediators for their biological functions are extracellular vesicles (MSC-Evs) and soluble cytokines derived from MSCs. The safety and efficacy of MSCs have been demonstrated in clinical Phase I / IIa trials for AD. This paper provides a comprehensive review of the pathogenesis of AD and the currently published studies on the function of MSCs and MSC-Evs in AD, primarily including the pathogenesis and the immunomodulatory impacts of MSCs and MSC-Evs, along with advancements in clinical studies. It provides insights for comprehending AD pathogenesis and investigating treatments based on MSCs.

3 August 2021 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
JLJingjing Liu
Jingjing Liu
XWXiaoxu Wang
Xiaoxu Wang
SWShufeng Wang
Shufeng Wang
FLFengxia Liu
Fengxia Liu
Background: Background: Rheumatoid Arthritis (RA) is a common connective tissue disease, characteristic of chronic and invasive synovitis in single or multiple joints and vasculitis. RA is a heterogeneous disease with unclear pathogenesis. Therefore, exploring the etiology and pathogenesis of the disease is essential for identifying new promising treatment strategies for RA. Accumulated data have implicated the significant role of non-coding RNA in RA, some of which are demonstrated to regulate inflammation and autoimmunity in RA through the Toll-Like Receptor (TLR) signaling pathway. To clarify the mechanism of non-coding RNA regulating the generation of proinflammatory mediators is helpful for understanding the pathogenesis of RA. Moreover, these well established non-coding RNAs can serve as novel biotargets for RA diagnosis and treatment. Conclusion: Here, we summarize currently available data on non-coding RNAs, TLRs, and the underlying molecular mechanisms in RA. This review will provide insight into the potential use of non-coding RNA as disease diagnosis and treatment markers for RA.